GSK raises annual forecasts again on strong Arexvy launch
Published
GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot. Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries…
#gsk #rsv #arexvy #heartburndrug #zantac